Compare · SGP vs SYK
SGP vs SYK
Side-by-side comparison of SpyGlass Pharma Inc. (SGP) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SGP and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $125.43B, about 159.5x SGP ($786.2M).
- Over the past year, SGP is down 10.3% and SYK is down 10.8% - SGP leads by 0.5 points.
- SYK has hit the wire 5 times in the past 4 weeks while SGP has been quiet.
- SYK has more recent analyst coverage (25 ratings vs 5 for SGP).
- Company
- SpyGlass Pharma Inc.
- Stryker Corporation
- Price
- $23.43-3.42%
- $327.50-0.63%
- Market cap
- $786.2M
- $125.43B
- 1M return
- -6.60%
- -0.03%
- 1Y return
- -10.26%
- -10.77%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- News (4w)
- 0
- 5
- Recent ratings
- 5
- 25
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest SGP
- SEC Form 10-K filed by SpyGlass Pharma Inc.
- SpyGlass Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
- H.C. Wainwright initiated coverage on SpyGlass Pharma with a new price target
- SpyGlass Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
- SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit
- Stifel initiated coverage on SpyGlass Pharma with a new price target
- Citigroup initiated coverage on SpyGlass Pharma with a new price target
- Jefferies initiated coverage on SpyGlass Pharma with a new price target
Latest SYK
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Berger Montague PC Investigates Stryker Corporation's Board of Directors for Breach of Fiduciary Duty (NYSE: SYK)
- Leerink Partners initiated coverage on Stryker with a new price target
- Stryker signs definitive agreement to acquire Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio
- Amendment: Stryker Corporation filed SEC Form 8-K: Regulation FD Disclosure
- Stryker to announce financial results for its first quarter of fiscal year 2026
- Stryker names Nick Mead Vice President, Investor Relations
- Amendment: SEC Form SCHEDULE 13G/A filed by Stryker Corporation
- SEC Form 4 filed by Stiles Spencer S
- SEC Form 4 filed by Pierce James Andrew